Bat­tling low ex­pec­ta­tions and go­liath ri­vals, Re­gen­eron/Sanofi add pos­i­tive Lib­tayo da­ta in pur­suit of block­buster sta­tus

Late­com­ers Re­gen­eron and Sanofi con­tin­ue to claw their way for­ward in the tough PD-(L)1 mar­ket. Re­searchers for the check­point al­lies of­fered a pos­i­tive piv­otal snap­shot of their PD-1 Lib­tayo ear­ly Tues­day, which could pro­vide an­oth­er boost in an on­col­o­gy mar­ket dom­i­nat­ed by Mer­ck’s Keytru­da and Bris­tol My­ers’ Op­di­vo.

The re­search team jour­neyed out in­to a pa­tient pop­u­la­tion with no ap­proved ther­a­py: basal cell car­ci­no­ma in pa­tients whose dis­ease had ad­vanced be­yond the reach of a Hedge­hog path­way in­hibitor — mean­ing Erivedge and Odom­zo. Right now, that’s the end of the line in the treat­ment par­a­digm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.